Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
A Phase I Clinical Trial of mTOR Inhibition With Sirolimus for Enhancing ALVAC(2)-NY-ESO-1(M)/TRICOM Vaccine Induced Anti-Tumor Immunity in Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Sponsor: National Cancer Institute (NCI)
This PHASE1 trial investigates Recurrent Fallopian Tube Cancer and Recurrent Ovarian Epithelial Cancer and is currently completed. National Cancer Institute (NCI) leads this study, which shows 14 recorded versions since 2012 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jan 2020 — Apr 2020 [monthly]
Active Not Recruiting PHASE1
▶ Show 9 earlier versions
-
Sep 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE1
-
Jul 2019 — Sep 2019 [monthly]
Active Not Recruiting PHASE1
-
Apr 2019 — Jul 2019 [monthly]
Active Not Recruiting PHASE1
-
Feb 2019 — Apr 2019 [monthly]
Active Not Recruiting PHASE1
-
Jan 2019 — Feb 2019 [monthly]
Active Not Recruiting PHASE1
-
Jun 2018 — Jan 2019 [monthly]
Active Not Recruiting PHASE1
-
Apr 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
-
Feb 2017 — Apr 2017 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Aug 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- Roswell Park Cancer Institute
- Sanofi Pasteur, a Sanofi Company
For direct contact, visit the study record on ClinicalTrials.gov .